Voluntis Collaborates with Eisai to Develop Digital Therapeutics for Oncology Patients

 Voluntis Collaborates with Eisai to Develop Digital Therapeutics for Oncology Patients

Voluntis Collaborates with Eisai to Develop Digital Therapeutics for Oncology Patients

Shots:

  • Voluntis enters into a license agreement with Eisai to design & develop DTx for patients and healthcare professionals to support cancer treatment, utilizing the Theraxium technology platform
  • The DTx will be designed with the intent to be commercialized in the US, Japan and EU, which will boost Voluntis’ pipeline and global footprint
  • Additionally, the partners will explore other opportunities to develop, evaluate and commercialize DTx in the field of neurology, notably AD and dementia

Click here to­ read full press release/ article | Ref: Businesswire | Image: Voluntis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post